Med. praxi. 2021;18(5):303-310 | DOI: 10.36290/med.2021.051

Dyslipidemias - a practical approach

MUDr. Barbora Nussbaumerová, Ph.D.
Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

Dyslipidemia/hypercholesterolemia is one of the most important cardiovascular risk factors. The new Guidelines of the European Society of Cardiology and European Atherosclerosis Society recommend how to stratify and decrease the cardiovascular risk according to the evidence based medicine and how to treat dyslipidemias. The lifestyle recommendations are the cornerstone, the pharmacotherapy is mostly started with statins. Ezetimibe and biological treatment of dyslipidemia find their place.

Keywords: dyslipidemia, cardiovascular risk, pharmacotherapy, statins, ezetimibe, fixed combinations.

Published: December 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. Dyslipidemias - a practical approach. Med. praxi. 2021;18(5):303-310. doi: 10.36290/med.2021.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifi cation to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-188. Go to original source... Go to PubMed...
    2. Vrablík M, Piťha J, Bláha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. AtheroRev 2019; 4(3): 126-137. Go to original source...
    3. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-1391. Go to original source... Go to PubMed...
    4. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010; 31(19): 2351-2358. Go to original source... Go to PubMed...
    5. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Eff ectiveness of the Heart Age tool for improving modifi able cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389-396. Go to original source... Go to PubMed...
    6. Cuende JI. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts Rev Esp Cardiol. 2016; 69(3): 243-246. Go to original source... Go to PubMed...
    7. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99(5): 673-680. doi: 10.1016/j.amjcard.2006.10.022. Go to original source... Go to PubMed...
    8. Češka R, Táborský M, Vrablík M. Společné stanovisko odborných společností k předepisování PCSK9 inhibitorů. Vnitř Lék 2018; 64(12): 1131-1136. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.